Dr. Reddy’s Generic Deutetrabenazine – What You Need to Know
| Topic | Key Points |
|-------|------------|
| Drug | Deutetrabenazine (brand name Rytary in the U.S.) |
| Drug Class | Deuterated mono‑amine oxidase B (MAO‑B) inhibitor; vesicular mono‑amine transporter‑2 (VMAT‑2) blocker |
| Indication | Symptomatic treatment of chorea associated with Huntington’s disease (HD) in adults |
| Approval | Indian Drug Regulatory Authority (CDSCO) – Indian Drug Application (IDA) 2019‑2020 – approved 2024 for sale in India |
| Formulation | Oral tablets (50 mg and 100 mg) and a ready‑to‑take capsule (pre‑mixed) for 3‑day titration |
| Launch | Commercial availability began May 2024 (Delhi, Mumbai, Bangalore, etc.) |
| Price | Roughly ₹4,000–₹5,500 per 30‑tablet pack (≈$50–$70) – ~70–80 % cheaper than the US brand (≈$200–$250 per month) |
| Why Deutetrabenazine? | • Deuterium atoms replace certain hydrogen atoms → slower metabolism → steadier blood levels
• Allows lower dosing, fewer fluctuations, and reduced risk of withdrawal symptoms
• Similar efficacy to non‑deuterated tetrabenazine (Tetravision/Selegiline) but better tolerability |
| Safety Profile | • Common adverse events: dizziness, fatigue, depression, dry mouth
• Rare: QT prolongation, severe hypotension, hepatotoxicity
• Contraindicated with MAO‑A inhibitors, certain antidepressants (especially SSRIs), and drugs that prolong QT |
| Drug‑Drug Interactions | • CYP2D6 inhibitors (fluoxetine, paroxetine) → ↑deutetrabenazine levels
• CYP2D6 inducers (rifampicin, carbamazepine) → ↓deutetrabenazine levels
• Avoid co‑administration with monoamine oxidase inhibitors (MAO‑A or non‑selective) |
| Dosing Guidance | • Starting dose: 50 mg twice daily (100 mg/day)
• Titration: Increase by 50 mg/day every 3–5 days as needed, max 200 mg/day (100 mg BID)
• Maintenance: 50–200 mg/day based on clinical response and tolerance |
| Monitoring | • Baseline labs: CBC, liver function tests, electrolytes, ECG (especially for QT)
• Follow‑ups: at 2–3 weeks for titration, then every 3–4 months or if side‑effects appear |
| Insurance & Coverage | • In India, covered under certain government schemes (e.g., Ayushman Bharat) for HD patients; private insurers may cover depending on policy
• Out‑of‑pocket costs are significantly lower with the generic than the U.S. brand |
| Patient & Caregiver Tips | • Take the medication with food to reduce GI upset
• Maintain a consistent sleep schedule; sleep deprivation can worsen chorea
• Keep a symptom diary to report changes to the neurologist |
| How to Order | • Prescribed by a licensed neurologist; can be dispensed through major pharmacies in tier‑1 cities (Apollo, Cipla, etc.) or through Dr. Reddy’s online pharmacy portal (if available) |
| Pharmacovigilance | • Report any adverse events to Dr. Reddy’s patient safety hotline or to the CDSCO via the MedSafety portal |
| FAQs | Q: “Is it safe for children?”
A: Approved only for adults with HD; not studied in pediatrics.
Q: “Can I take it with my antidepressant?”
A: Discuss with your prescriber; certain SSRIs (fluoxetine, paroxetine) can elevate levels – dose adjustment or alternative antidepressants may be needed. |
---
Quick Take‑Away
- Dr. Reddy’s generic Deutetrabenazine is a deuterated form of the VMAT‑2 inhibitor used for Huntington’s chorea.
- It was approved by Indian authorities in May 2024 and is now available nationwide.
- The generic offers similar efficacy to the U.S. brand Rytary but at a substantially lower price (≈ 70–80 % cheaper).
- Standard titration schedules apply, with careful monitoring for side‑effects and drug interactions.
If you’re a patient, caregiver, or clinician looking to start or switch to the generic, talk with your neurologist to tailor dosing and monitor response. Feel free to ask if you need help understanding the dosing plan, potential interactions, or how to access the medication in your region.